Core Insights - Gilead Sciences reported a strong performance in its HIV segment, with full-year sales reaching $20.8 billion, a 6% increase year-over-year, and fourth-quarter sales hitting a record $5.8 billion, also up 6% [1][6]. Financial Performance - Total product sales for the fourth quarter were $7.9 billion, a 5% increase year-over-year, while excluding Veklury, sales were $7.7 billion, up 7% [2]. - For the full year 2025, Gilead's total product sales were $28.9 billion, up 1% from 2024, exceeding guidance [3]. - The base business sales, excluding Veklury, were $28.0 billion, up 4% year-over-year, and would have been 8% without the impact of the Medicare Part D redesign [2][6]. HIV Business Highlights - The HIV business faced a $900 million headwind from the Part D redesign in 2025, but management indicated that excluding this impact, HIV sales grew by 10% [1]. - Biktarvy, a key treatment, generated fourth-quarter sales of $4.0 billion, up 5% year-over-year, and full-year sales of $14.3 billion, up 7% [7]. - The injectable HIV prevention product Sunlenca generated $150 million in 2025, with management forecasting about $800 million in revenue for 2026 [8][9]. Liver and Oncology Performance - Gilead's liver disease business grew 6% in 2025 to $3.2 billion, with fourth-quarter sales of $844 million, up 17% year-over-year, driven by the adoption of Livdelzi [12]. - In oncology, Trodelvy sales rose 6% in 2025 to $1.4 billion, with fourth-quarter sales of $384 million, up 8% year-over-year [13]. Future Guidance and Pipeline - For 2026, Gilead expects total product sales of $29.6 billion to $30.0 billion, with base business sales projected to grow 4% to 5% [21]. - The company plans multiple potential launches in 2026, including Trodelvy for first-line TNBC and a combination therapy for HIV [5][18]. - Management anticipates a product gross margin of about 87% and non-GAAP diluted EPS of $8.45 to $8.85 for 2026 [22]. Capital Return Strategy - Gilead returned $5.9 billion to shareholders in 2025, including $1.9 billion in share repurchases, and aims to return at least 50% of free cash flow to shareholders [24].

Financial Data and Key Metrics Changes - For the full year 2025, total product sales were $28.9 billion, up 1% from 2024, exceeding guidance due to strong HIV sales growth [34][36] - Base business revenue, excluding Veklury, was $28 billion, up nearly 4% from 2024, also exceeding guidance [34][36] - Non-GAAP diluted EPS for 2025 was $8.15, in line with guidance, driven by lower R&D expenses and higher revenues [38][40] Business Line Data and Key Metrics Changes - The HIV business grew 6% year-over-year to $20.8 billion, driven by strong demand for Biktarvy and Descovy [35][12] - Liver disease sales reached $3.2 billion, up 6% year-over-year, primarily due to Livdelzi's performance [19][35] - Oncology sales from Trodelvy increased 6% to $1.4 billion, driven by demand in metastatic breast cancer treatment [20][21] Market Data and Key Metrics Changes - The HIV prevention portfolio grew 53% year-over-year, with Descovy sales up 31% and Yes2Go achieving $150 million in full-year sales [15][17] - The liver market share for Livdelzi exceeded 50% in second-line PBC, reflecting strong demand and competitive dynamics [19] - Cell therapy sales were $1.8 billion, down 7% year-over-year, impacted by competitive pressures [22][35] Company Strategy and Development Direction - The company is targeting four commercial launches in 2026, including Trodelvy for first-line metastatic triple-negative breast cancer and Biclen for HIV treatment [8][24] - Gilead aims to maintain expense discipline while investing in new product launches and M&A opportunities [9][44] - The company is well-positioned for growth with no major product losses expected until 2036, entering 2026 with a strong pipeline [9][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong performance and growth potential, highlighting a robust pipeline with up to 10 ongoing and potential new launches through 2027 [9][44] - The company anticipates a 2% headwind to growth in 2026 due to drug pricing agreements and changes to the Affordable Care Act [42] - Management expects total HIV sales to grow approximately 6% in 2026, with Yes2Go projected to generate $800 million in revenue [42][17] Other Important Information - The company returned $5.9 billion to shareholders in 2025, including $1.9 billion in share repurchases [43][44] - R&D expenses for 2025 were $5.7 billion, down 1% from 2024, reflecting disciplined investment in clinical programs [36][38] Q&A Session Summary Question: Can you elaborate on the assumptions driving the $800 million guidance for Yes2Go? - Management highlighted strong access with 90% payer coverage and ongoing DTC campaigns to increase awareness and drive growth [46][48] Question: What type of share gains do you expect for Anito-cel in the fourth-line setting? - Management expects modest contributions in 2026 post-approval, with a goal to become the market leader over time due to efficacy and safety profiles [54][56] Question: Are you expecting cannibalization of Descovy PrEP sales as early as this year? - Management believes both Yes2Go and Descovy will grow in 2026, with Yes2Go expected to take the lead in the long term [59][62] Question: What do you need to show out of Purpose 365 to support approval for the once-yearly injectable lenacapavir? - The study aims to demonstrate target coverage and pharmacokinetics, with potential market expansion opportunities identified [71][76]

Summary of Vir Biotechnology FY Conference Call - December 03, 2025 Company Overview - **Company**: Vir Biotechnology (NasdaqGS:VIR) - **Focus**: Development of innovative therapies for infectious diseases and cancer, particularly through T cell engagers and hepatitis programs Key Accomplishments in 2025 - **Clinical Programs**: Significant advancements in three clinical-stage T cell engagers and a registration program for hepatitis delta [2][4] - **Data Reporting**: First-time reporting of data on Vir-5500 (PSMA CD3 T cell engager) and Vir-5818 (HER2 CD3 T cell engager) with promising early results [2][3] - **Hepatitis Delta Program**: Achieved transformative data with 66% of patients achieving undetectable virus levels after 48 weeks of treatment [4] Clinical Development Highlights - **Vir-5500**: - Unique dual masking technology enhances safety and efficacy by preventing toxicity associated with naked PSMA T cell engagers [8][10] - Extended half-life of 8-10 days allows for less frequent dosing [10] - Early clinical data showed 58% of patients achieving a PSA reduction of 50, with only 25% experiencing any CRS (cytokine release syndrome) [15][16] - **Hepatitis Delta**: - Phase two Solstice trial demonstrated significant efficacy, with 66% of patients achieving target not detected status [4][30] - Enrollment for phase three trials (Eclipse) completed ahead of schedule, indicating strong demand for therapy [32] Differentiation and Competitive Landscape - **Masking Technology**: - Vir-5500 utilizes a dual masking approach that is distinct from single mask competitors, providing a better therapeutic index [21][22] - The Xtend mask technology has been validated in other marketed drugs, enhancing confidence in safety and efficacy [11][22] - **Market Positioning**: - Potential to position Vir-5500 in both pre- and post-Pluvicto treatment settings, aiming for a balance of efficacy and safety [26][27] Future Expectations - **Upcoming Data**: - Next data cut expected in January will focus on early readouts such as PSA levels and safety data, with a meaningful dataset anticipated [24] - **Product Presentation**: - Anticipated to be two subcutaneous injections, allowing for at-home administration or by healthcare professionals [33] Industry Insights - **Feedback from Medical Community**: - Positive reception from KOLs regarding the unmet medical need in hepatitis delta, with enthusiasm for the efficacy demonstrated in clinical trials [29][30] - **Enrollment Trends**: - Rapid enrollment in Eclipse trials reflects strong demand and interest in the hepatitis delta treatment [32] Conclusion - Vir Biotechnology has made significant strides in its clinical programs, particularly with its innovative masking technology for T cell engagers and promising results in its hepatitis delta program. The company is well-positioned to address unmet medical needs in both oncology and infectious diseases, with strong support from the medical community and a clear path forward for upcoming data releases and product development.